

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Cancel claims 1-10.

11. (New) A method of treating a patient having hemophilia B comprising administering to said patient a hemophilia B symptom preventing or ameliorating amount of a biologically active human Factor IX produced by at least one transgenic pig.

12. (New) The method of claim 11, wherein said biologically active human Factor IX further comprises a pharmaceutically acceptable carrier.

13. (New) The method of claim 11, wherein said biologically active human Factor IX comprises a specific activity greater than the specific activity of plasma-derived human Factor IX.

14. (New) The method of claim 11, wherein said biologically active human Factor IX comprises a specific activity of greater than 250 U/mg.

15. (New) The method of claim 11, wherein said biologically active human Factor IX comprises a specific activity of at least approximately 337 U/mg.

16. (New) The method of claim 11, wherein said biologically active human Factor IX comprises a half-life in circulation of at least approximately 24 hours.

17. (New) The method of claim 11, wherein said biologically active human Factor IX comprises sufficient gamma-carboxylation and post-translational modification to initiate clotting in Factor IX-deficient human plasma.

18. (New) The method of claim 11, wherein said administration of said human Factor IX raises Factor IX levels 20% or greater in the blood.

19. (New) A purified biologically active human Factor IX produced in a transgenic pig.

20. (New) The biologically active human Factor IX of claim 19, further comprising a pharmaceutically acceptable carrier.

21. (New) The biologically active human Factor IX of claim 19, wherein said biologically active human Factor IX comprises a specific activity greater than the specific activity of plasma-derived human Factor IX.

22. (New) The biologically active human Factor IX of claim 19, wherein said biologically active human Factor IX comprises a specific activity of greater than 250 U/mg.

23. (New) The biologically active human Factor IX of claim 19, wherein said biologically active human Factor IX comprises a specific activity of at least approximately 337 U/mg.

24. (New) The biologically active human Factor IX of claim 19, wherein said biologically active human Factor IX comprises a half-life in circulation of at least approximately 24 hours.

25. (New) The biologically active human Factor IX of claim 19, wherein said biologically active human Factor IX comprises sufficient gamma-carboxylation and post-translational modification to initiate clotting in Factor IX-deficient human plasma.

26. (New) Milk of a transgenic pig comprising biologically active human Factor IX produced in a transgenic pig.